| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-36 |
| filingDate |
2003-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f751dacd62db23660f106f52ff8f939 |
| publicationDate |
2004-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2004101573-A1 |
| titleOfInvention |
Injectable composition for cancer treatment |
| abstract |
An intravenous pharmaceutical composition comprising an aqueous solution of arsenic trioxide and sodium chloride. The composition is effective in the treatment of cancers including leukemia. Complete remission of up to 21 years have been observed for acute promyclocytic leukemia patients. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10653628-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10111836-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016123603-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10272045-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019141988-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400112-B2 |
| priorityDate |
1995-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |